BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34357362)

  • 1. Local delivery to malignant brain tumors: potential biomaterial-based therapeutic/adjuvant strategies.
    Alghamdi M; Gumbleton M; Newland B
    Biomater Sci; 2021 Sep; 9(18):6037-6051. PubMed ID: 34357362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationally designed drug delivery systems for the local treatment of resected glioblastoma.
    Bastiancich C; Malfanti A; Préat V; Rahman R
    Adv Drug Deliv Rev; 2021 Oct; 177():113951. PubMed ID: 34461201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma.
    Pena ES; Graham-Gurysh EG; Bachelder EM; Ainslie KM
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing Next-Generation Local Drug Delivery Vehicles for Glioblastoma Adjuvant Chemotherapy: Lessons from the Clinic.
    Tabet A; Jensen MP; Parkins CC; Patil PG; Watts C; Scherman OA
    Adv Healthc Mater; 2019 Feb; 8(3):e1801391. PubMed ID: 30632715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.
    Graham-Gurysh E; Moore KM; Satterlee AB; Sheets KT; Lin FC; Bachelder EM; Miller CR; Hingtgen SD; Ainslie KM
    Mol Pharm; 2018 Mar; 15(3):1309-1318. PubMed ID: 29342360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric Biomaterial Scaffolds for Tumoricidal Stem Cell Glioblastoma Therapy.
    Moore KM; Murthy AB; Graham-Gurysh EG; Hingtgen SD; Bachelder EM; Ainslie KM
    ACS Biomater Sci Eng; 2020 Jul; 6(7):3762-3777. PubMed ID: 33463324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
    Yang J; Shi Z; Liu R; Wu Y; Zhang X
    Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
    Bastiancich C; Danhier P; Préat V; Danhier F
    J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in drug delivery technology for the treatment of glioblastoma multiforme.
    Cha GD; Kang T; Baik S; Kim D; Choi SH; Hyeon T; Kim DH
    J Control Release; 2020 Dec; 328():350-367. PubMed ID: 32896613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
    Juratli TA; Schackert G; Krex D
    Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and structure-property relationships of an injectable thiol-Michael addition hydrogel toward compatibility with glioblastoma therapy.
    Khan ZM; Wilts E; Vlaisavljevich E; Long TE; Verbridge SS
    Acta Biomater; 2022 May; 144():266-278. PubMed ID: 35296443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Vascular Drug Delivery in Cerebral Cancer.
    Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
    Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents.
    Hasbum A; Quintanilla J; Jr JAA; Ding MH; Levy A; Chew SA
    Future Med Chem; 2021 Feb; 13(4):393-418. PubMed ID: 33399488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
    Dréan A; Goldwirt L; Verreault M; Canney M; Schmitt C; Guehennec J; Delattre JY; Carpentier A; Idbaih A
    Expert Rev Neurother; 2016 Nov; 16(11):1285-1300. PubMed ID: 27310463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel delivery methods bypassing the blood-brain and blood-tumor barriers.
    Hendricks BK; Cohen-Gadol AA; Miller JC
    Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
    Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
    Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
    Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.